Skip to content

Effect of flurbiprofen axetil on postoperative renal function in patients undergoing percutaneous nephroscopic surgery: a prospective, randomized, double-blind, controlled clinical study

Effect of flurbiprofen axetil on postoperative renal function in patients undergoing percutaneous nephroscopic surgery: a prospective, randomized, double-blind, controlled clinical study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500097464
Enrollment
Unknown
Registered
2025-02-19
Start date
2025-03-01
Completion date
Unknown
Last updated
2025-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute kidney injury

Interventions

Flurbiprofen axetil group:flurbiprofen axidate 100mg was injected intravenously after the operation and before recovery from anesthesia
Control group:10ml of normal saline was injected intravenously after the operation and before recovery from anesthesia

Sponsors

Huadu District People's Hospital of Guangzhou
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients with normal serum creatinine and eGFR before surgery 2. Patients undergoing percutaneous nephrolithotomy under general anesthesia; 3.ASA grades 1-3; 4. BMI>18Kg/m2 and <30Kg/m2; 5. Patients or their family members can provide written informed consent.

Exclusion criteria

Exclusion criteria: 1. Perioperative use of other non-steroidal anti-inflammatory drugs; 2. Patients with contraindications to the use of flurbiprofen exate; 3. Preoperative CKD stage 3 (eGFR 1500ml); 8. Intraoperative hypotension (blood pressure below 90/60mmHg or MAP< 60mmHg for more than 20 minutes); 9. Patients in critical condition who need to be admitted to ICU for further treatment after surgery; 10. Severe liver dysfunction (Child-Pugh grade C); 11. Difficulty in follow-up and request for withdrawal from the investigator; 12. Patients with sepsis ;

Design outcomes

Primary

MeasureTime frame
Serum creatinine;Neutrophil gelatinase-associated lipocalin;Cystatin C;

Countries

China

Contacts

Public ContactDong Wang

Huadu District People's Hospital of Guangzhou

905486084@qq.com+86 191 1813 0951

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026